No Data
Buy Rating for Silence Therapeutics: Promising Phase 1 Results and Future Prospects
We're Hopeful That Silence Therapeutics (NASDAQ:SLN) Will Use Its Cash Wisely
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading
Express News | Silence Therapeutics - From Time to Time, Co or Any Selling Shareholder May Offer and Sell Ordinary Shares
Express News | Silence Therapeutics PLC Files for Stock Shelf; Size Not Disclosed - SEC Filing
Morgan Stanley Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $49
No Data
No Data